Before considering participating in a clinical trial, talk with a healthcare provider you trust about your options, talk with those who have participated in clinical trials, and try to gather as much information as you can. The resources on our Considering Treatment page may help.
Clinical trial participates must meet certain criteria and are asked to submit questionnaires, blood work, and other lab results for research purposes. As well as a commitment to the course of treatment, there is a time commitment to complete all of the data collection required.
Clinical Trials Currently or About to be Recruiting in Canada
Clinical Trial Title: Effectiveness of Paritaprevir/r – Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada (AMBER)
Sponsor: AbbVie
Canadian Locations: Vancouver, Barrie, Belleville, Brampton, Calgary, Moncton, Ottawa, Quebec City, Toronto, Saskatoon, Sherbrooke, Saint John, Victoria, Westminster, Winnipeg
Recruiting Status: Not yet recruiting in Calgary, Fredricton, Halifax, Hamilton, Montreal, Regina, Toronto, Victoria
Information Last Updated: April 2016
More Information
Clinical Trial Title: A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (ZIRCON)
Sponsor: AbbVie
Canadian Locations: Edmonton
Recruiting Status: Not yet recruiting
Information Last Updated: April 2016
More Information
Clinical Trial Title: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)
Sponsor: AbbVie
Canadian Locations: Calgary, Winnipeg, Toronto
Information Last Updated: April 2016
More Information
Clinical Trial Title: A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (ENDURANCE-3)
Sponsor: AbbVie
Canadian Locations: Vancouver, Winnipeg, Montreal, Toronto
Information Last Updated: April 2016
More Information
Clinical Trial Title: The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
Sponsor: AbbVie
Canadian Locations: Montreal, Ottawa, Toronto
Information Last Updated: April 2016
More Information
Clinical Trial Title: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
Sponsor: AbbVie
Canadian Locations: Vancouver, Calgary, Edmonton, Montreal, Ottawa, Quebec City, Saint John, Toronto, Vaughan, Winnipeg
Information Last Updated: January 2016
More Information
Clinical Trial Title: A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
Sponsor: AbbVie
Canadian Locations: Edmonton
Information Last Updated: April 2016
More Information
Clinical Trial Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
Sponsor: AbbVie
Canadian Locations: Calgary, Edmonton, Montreal, Ottawa, Vaughan
Recruiting Status: Not yet recruiting in Ottawa
Information Last Updated: February 2016
More Information
Clinical Trial Title: Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Sponsor: Bristol-Myers Squibb
Canadian Locations: Vancouver, Calgary, Edmonton, Victoria, Toronto
Information Last Updated: April 2016
More Information
Clinical Trial Title: Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
Sponsor: Gilead
Canadian Locations Recruiting: Vancouver, Calgary, Edmonton, Brampton, Montreal, Toronto
Information Last Updated: April 2016
More Information
Clinical Trial Title: Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-1)
Sponsor: Gilead
Canadian Locations Recruiting: Vancouver, Brampton, Calgary, Edmonton, Montreal, Toronto
Information Last Updated: April 2016
More Information
Clinical Trial Title: Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. (REACT)
Sponsor: Kirby Institute
Canadian Locations Not Yet Recruiting: Montreal, Toronto
Information Last Updated: December 2015
More Information
Clinical Trial Title: Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Sponsor: Gilead
Canadian Locations Recruiting: Vancouver, Calgary, Edmonton, Brampton, Toronto, Ottawa, Montreal
Information Last Updated: April 2016
More Information
Clinical Trial Title: Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2)
Sponsor: Gilead
Canadian Locations Recruiting: Vancouver, Brampton, Calgary, Edmonton, Ottawa, Toronto, Montreal
Information Last Updated: April 2016
More Information
Clinical Trial Title: Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
Sponsor: Gilead
Canadian Locations: Vancouver
Information Last Updated: March 2016
More Information
Clinical Trial Title: Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3 Infection (MK-3682-012)
Sponsor: Merck & Dohme Corp.
Canadian Locations: Kirkland, Quebec
Information Last Updated: April 2016
More Information
Clinical Trial Title: Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)
Sponsor: University Health Network, Toronto
Canadian Locations: Toronto
Information Last Updated: February 2016
More Information
Clinical Trial Title: Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
Sponsor: University Health Network, Toronto
Canadian Locations Not Yet Recruiting: Toronto
Information Last Updated: November 2015
More Information
Page Last Revised: April 22, 2016.